R1 RCM — FY2019 Earnings Presentation
13 slides from R1 RCM's earnings presentation, Feb 20, 2020
Slide 1: Fourth Quarter and Full Year 2019 Results Conference Call
Exhibit 99.2 Fourth Quarter and Full Year 2019 Results Conference Call February 20, 2020
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward‐Looking Statements and Non‐GAAP Financial Measures This presentation includes information that may constitute “forward‐looking statements,” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward‐looking statements relate to future, not pa
Slide 3: Q4 and Full Year 2019 Financial Highlights
Q4 and Full Year 2019 Financial Highlights Fourth Quarter Financial Highlights . Revenue of $314.0 million, up $51.1 million and 19.4% compared to the same period last year . GAAP net income of $7.8 million, compared to GAAP net loss of $5.7 million in the same period last year . Adjusted EBITDA of
Slide 4: 2019 Business Highlights
2019 Business Highlights Strong Operational Execution on Contracted Book of Business . Faster margin progression relative to our model targets for customers in the margin‐ramp phase New Business Wins . $4.1 billion in new end‐to‐end net patient revenue (NPR) under management from net new customers,
Slide 5: 2020 Priorities
2020 Priorities New Business Growth . Market dynamics remain favorable and pipeline continues to grow . Deals in late‐stage pipeline at the end of 2019 continue to progress . Anticipate signing $3 billion in new NPR in 2020 Integrate SCI and commercialize PX platform . Integrate SCI’s digital patien
Slide 6: 4Q'19 non-GAAP Results – Q/Q and Y/Y Comparison
4Q’19 non‐GAAP Results –Q/Q and Y/Y Comparison ($ in millions) 4Q’19 3Q’19 4Q’18 Key change driver(s) • Q/Q: Contribution from Quorum Revenue $314.0 $301.2 $262.9 • Y/Y: Contribution from new customers onboarded in 2019 • Q/Q: Quorum onboarding costs • Y/Y: New customer onboarding Adjusted Cost of S
Slide 7: 2019 vs. 2018 Results (non-GAAP)
2019 vs. 2018 Results (non‐GAAP) ($ in millions) 2019 2018 y/y chg. Key change driver(s) • Onboarding of new customers and Revenue $1,186.1 $868.5 36.6% a full year of Intermedix • Onboarding of new customers, offset in part by productivity Adjusted Cost of Services1 $930.0 $731.7 27.1% improvement
Slide 8: Additional Commentary
Additional Commentary . Net debt1 of $264.4 million as of 12/31/19, including restricted cash . Repaid $14 million in Q4’19; $28 million in 2H’19 . Expect to fund $150 million of SCI acquisition with incremental Term Loan A . Net interest expense of $4.0 million in Q4’19; $29.1 million in 2019 . Dow
Slide 9: Financial Outlook
Financial Outlook 2 2020 2021 1 Cash flow from operations expected to grow ~$100M in 2020 Note1: Adjusted EBITDA is a non‐GAAP measure. Pease refer to the Appendix for a reconciliation of non‐GAAP financial measures. 9 Note2: Long‐term is defined as 3‐5 years post‐2020. 2020 guidance continues to as
Slide 10: Appendix
Appendix 10
Slide 11: Use of Non-GAAP Financial Measures
Use of Non‐GAAP Financial Measures . In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non‐GAAP financial performance mea
Slide 12: Reconciliation of GAAP to non-GAAP Financials
Reconciliation of GAAP to non‐GAAP Financials $ in millions Reconciliation of GAAP Net Income (Loss) to non‐GAAP Adjusted EBITDA Three Months Ended Year Ended Three Months Ended December 31, December 31, September 30, 2019 2018 2019 2018 2019 Net income (loss) $ 7.8 $ (5.7) $ 12.0 $ (45.3) $ 9.2 Net
Slide 13: Reconciliation of GAAP to non-GAAP Financials
Reconciliation of GAAP to non‐GAAP Financials $ in millions Reconciliation of GAAP Operating Income Guidance to Non‐GAAP Adjusted EBITDA Guidance 2020 2021 GAAP Operating Income Guidance $145‐165 $205‐225 Plus: Depreciation and amortization expense $65‐75 $75‐85 Share‐based compensation expense $20‐